Division of Cardiology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
Calcium-release deficiency syndrome (CRDS), which is caused by loss-of-function variants in cardiac ryanodine receptor 2 (RyR2), is an emerging cause of ventricular fibrillation. However, the lack of complex polymorphic/bidirectional ventricular tachyarrhythmias during exercise stress testing (EST) may distinguish it from catecholaminergic polymorphic ventricular tachycardia (CPVT). Recently, in the first clinical series describing the condition, mouse and human studies showed that the long-burst, long-pause, short-coupled ventricular extra stimulus (LBLPS) electrophysiology protocol reliably induced CRDS ventricular arrhythmias. Data from larger populations with CRDS and its associated spectrum of disease are lacking.
To further insight into CRDS through international collaboration.
DESIGN, SETTING, AND PARTICIPANTS: In this multicenter observational cohort study, probands with unexplained life-threatening arrhythmic events and an ultrarare RyR2 variant were identified. Variants were expressed in HEK293 cells and subjected to caffeine stimulation to determine their functional impact. Data were collected from September 1, 2012, to March 6, 2021, and analyzed from August 9, 2015, to March 6, 2021.
The functional association of RyR2 variants found in putative cases of CRDS and the associated clinical phenotype(s).
Of 10 RyR2 variants found in 10 probands, 6 were loss-of-function, consistent with CRDS (p.E4451del, p.F4499C, p.V4606E, p.R4608Q, p.R4608W, and p.Q2275H) (in 4 [67%] male and 2 [33%] female probands; median age at presentation, 22 [IQR, 8-34] years). In 5 probands with a documented trigger, 3 were catecholamine driven. During EST, 3 probands with CRDS had no arrhythmias, 1 had a monomorphic couplet, and 2 could not undergo EST (deceased). Relatives of the decedents carrying the RyR2 variant did not have EST results consistent with CPVT. After screening 3 families, 13 relatives were diagnosed with CRDS, including 3 with previous arrhythmic events (23%). None had complex ventricular tachyarrhythmias during EST. Among the 19 confirmed cases with CRDS, 10 had at least 1 life-threatening event at presentation and/or during a median follow-up of 7 (IQR, 6-18) years. Two of the 3 device-detected ventricular fibrillation episodes were induced by a spontaneous LBLPS-like sequence. β-Blockers were used in 16 of 17 surviving patients (94%). Three of 16 individuals who were reportedly adherent to β-blocker therapy (19%) had breakthrough events.
The results of this study suggest that calcium-release deficiency syndrome due to RyR2 loss-of-function variants mechanistically and phenotypically differs from CPVT. Ventricular fibrillation may be precipitated by a spontaneous LBLPS-like sequence of ectopy; however, CRDS remains difficult to recognize clinically. These data highlight the need for better diagnostic tools and treatments for this emerging condition.
钙释放缺陷综合征(CRDS)是由心脏兰尼碱受体 2(RyR2)功能丧失变异引起的,是心室颤动的一个新兴原因。然而,在运动应激测试(EST)期间缺乏复杂的多形性/双向室性心动过速可能将其与儿茶酚胺多形性室性心动过速(CPVT)区分开来。最近,在首次描述该病症的临床系列研究中,小鼠和人类研究表明,长爆发、长停顿、短耦合的心室额外刺激(LBLPS)电生理学方案可可靠地诱发 CRDS 室性心律失常。缺乏 CRDS 及其相关疾病谱的更大人群的数据。
通过国际合作进一步了解 CRDS。
设计、地点和参与者:在这项多中心观察性队列研究中,确定了具有不明原因的危及生命的心律失常事件和超罕见 RyR2 变异的先证者。在 HEK293 细胞中表达变异体,并进行咖啡因刺激以确定其功能影响。数据收集于 2012 年 9 月 1 日至 2021 年 3 月 6 日,并于 2015 年 8 月 9 日至 2021 年 3 月 6 日进行分析。
RyR2 变异在疑似 CRDS 病例中的功能关联及其相关临床表型。
在 10 个先证者中发现了 10 个 RyR2 变异,其中 6 个为功能丧失性变异,符合 CRDS(p.E4451del、p.F4499C、p.V4606E、p.R4608Q、p.R4608W 和 p.Q2275H)(在 4 [67%]名男性和 2 [33%]名女性先证者中;发病时的中位年龄为 22 [IQR,8-34]岁)。在有记录触发因素的 5 个先证者中,有 3 个是儿茶酚胺驱动的。在 EST 期间,3 名 CRDS 先证者没有心律失常,1 名先证者发生单形性成对,2 名先证者无法进行 EST(已死亡)。携带 RyR2 变异的死者亲属的 EST 结果不符合 CPVT。在筛查 3 个家庭后,13 名亲属被诊断为 CRDS,其中 3 名以前有过心律失常事件(23%)。在 EST 期间,没有人发生复杂的室性心动过速。在 19 例确诊的 CRDS 患者中,有 10 例在发病时和/或中位随访 7(IQR,6-18)年期间至少有 1 次危及生命的事件。2 例自发性 LBLPS 样序列诱发的室颤事件。17 名存活患者中有 16 名(94%)使用了β受体阻滞剂。在 16 名据称遵医嘱服用β受体阻滞剂的个体中(19%),有 3 人出现突破性事件。
这项研究的结果表明,由于 RyR2 功能丧失变异引起的钙释放缺陷综合征在机制和表型上与 CPVT 不同。自发性 LBLPS 样异位序列可能引发心室颤动;然而,CRDS 在临床上仍难以识别。这些数据突出了为这种新兴疾病开发更好的诊断工具和治疗方法的必要性。